Most Recent
ASX-listed biotech 4D Medical has sued competitor Cyclopharm alleging the company made false, misleading and malicious statements about its rival during an online webinar prompted by a "fake" question.
A judge has declined car dealer software supplier Pentana's bid to withdraw admissions made over four years ago in a dispute with competitor Titan DMS.
The ACCC will not stand in the way of Elders’ $475 million takeover of rival farm supplier Delta Agribusiness, after the agribusiness giant provided an undertaking to divest six Delta stores in Western Australia.
The competition regulator has expressed worries that Yamaha Motor's proposed acquisition of aluminium trailer boat maker Telwater could substantially lessen competition in the wholesale supply of outboard motors.
Western Sydney University is facing a class action alleging it misled students into studying a health engineering degree that was unaccredited, on the heels of similar claims being leveled at the University of Newcastle.
Commonwealth Bank's New Zealand unit, ASB Bank, has agreed to pay $119.35 million to settle a class action alleging it failed to repay fees and interest wrongly charged to 150,000 customers who took out home or personal loans.
Telstra has been ordered to pay $18 million in ACCC proceedings, after a court found the telco misled thousands of broadband customers about the speed of its budget internet provider Belong.
Mayfield Developments has argued the High Court should overturn a finding that NSW Ports was protected by derivative Crown immunity in entering allegedly uncompetitive agreements to privatise two ports, saying the decision could have “startling” consequences such as allowing the state to devise cartel arrangements.
A judge has allowed a class action over Isuzus that allegedly contained emissions cheat devices to send an opt out notice to group members that includes a warning that if they sell their cars, they may “lose some or all of the money” they could receive in any settlement.
Pharmaceutical giant Johnson & Johnson has denied knowingly selling alleged ineffective medications under its Benadryl, Sudafed and Codral brands, saying research indicated the phenylephrine-containing products worked.